Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

被引:131
作者
Imbertson, LM
Beaurline, JM
Couture, AM
Gibson, SJ
Smith, RMA
Miller, RL
Reiter, MJ
Wagner, TL
Tomai, MA
机构
[1] 3M Co, Pharmaceut, Dept Pharmacol, 3M Ctr, St Paul, MN 55144 USA
[2] 3M Co, Convent Dosage Forms, 3M Ctr, St Paul, MN 55144 USA
关键词
immunomodulator; interferon; interleukin; tumor necrosis factor;
D O I
10.1046/j.1523-1747.1998.00174.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
ALDARA (imiquimod cream 5%) recently became available for the treatment of genital and perianal warts; however, the topical mechanism of action of imiquimod is not fully understood. Imiquimod, and its analogs R-842, S-27609, and S-28463, are potent anti-viral and anti-tumor agents in animal models. Much of the biologic activity of these compounds can be attributed to the induction of cytokines, including interferon-alpha, tumor necrosis factor-alpha, interleukins-1, -6, -8, and others. This study was performed to characterize the response of mice and rats to topical application of imiquimod and S-28463 and also to evaluate these agents in cultures of murine and human skin cells. Topical administration of imiquimod or S-28463 to the flanks of hairless mice and rats leads to increases in local concentrations of interferon and tumor necrosis factor in the skin. The concentrations of interferon and tumor necrosis factor were higher at the site of drug application than in skin from the contralateral flank or skin from untreated animals. Interferon-alpha mRNA levels were also elevated in the skin of mice after topical application of either imiquimod or S-28463. In vitro, both imiquimod and S-28463 induced increases in interferon and tumor necrosis factor in cultures of cells isolated from hairless mouse skin. Imiquimod also increased interleukin-8 concentrations in human keratinocyte and fibroblast cultures, whereas S-28463 induced increases in tumor necrosis factor in fibroblast cultures. These results demonstrate that imiquimod and S-28463 stimulate production of cytokines in the skin after topical application, which may play a major role in its activity in genital wart patients.
引用
收藏
页码:734 / 739
页数:6
相关论文
共 28 条
[1]   EFFECTS OF THE IMMUNOMODULATING AGENT R837 ON ACUTE AND LATENT HERPES-SIMPLEX VIRUS TYPE-2 INFECTIONS [J].
BERNSTEIN, DI ;
HARRISON, CJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1511-1515
[2]   EFFICACY OF S26308 AGAINST GUINEA-PIG CYTOMEGALO-VIRUS INFECTION [J].
CHEN, M ;
GRIFFITH, BP ;
LUCIA, HL ;
HSIUNG, GD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :678-683
[3]  
CHODAKEWITZ JA, 1990, J IMMUNOL, V144, P2190
[4]   Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production [J].
Fujisawa, H ;
Shivji, GM ;
Kondo, S ;
Wang, BH ;
Tomai, MA ;
Miller, RL ;
Sauder, DN .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (07) :555-559
[5]   CELLULAR-REQUIREMENTS FOR CYTOKINE PRODUCTION IN RESPONSE TO THE IMMUNOMODULATORS IMIQUIMOD AND S-27609 [J].
GIBSON, SJ ;
IMBERTSON, LM ;
WAGNER, TL ;
TESTERMAN, TL ;
REITER, MJ ;
MILLER, RL ;
TOMAI, MA .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1995, 15 (06) :537-545
[6]   RELEASE OF BOTH PREFORMED AND NEWLY SYNTHESIZED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA)/CACHECTIN BY MOUSE MAST-CELLS STIMULATED VIA THE FC-EPSILON-RI - A MECHANISM FOR THE SUSTAINED ACTION OF MAST-CELL DERIVED TNF-ALPHA DURING IGE-DEPENDENT BIOLOGICAL RESPONSES [J].
GORDON, JR ;
GALLI, SJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :103-107
[7]   POSTTHERAPY SUPPRESSION OF GENITAL HERPES-SIMPLEX VIRUS (HSV) RECURRENCES AND ENHANCEMENT OF HSV-SPECIFIC T-CELL MEMORY BY IMIQUIMOD IN GUINEA-PIGS [J].
HARRISON, CJ ;
MILLER, RL ;
BERNSTEIN, DI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2059-2064
[8]   EFFECTS OF CYTOKINES AND R-837, A CYTOKINE INDUCER, ON UV-IRRADIATION AUGMENTED RECURRENT GENITAL HERPES IN GUINEA-PIGS [J].
HARRISON, CJ ;
STANBERRY, LR ;
BERNSTEIN, DI .
ANTIVIRAL RESEARCH, 1991, 15 (04) :315-322
[9]   MODIFICATION OF IMMUNOLOGICAL RESPONSES AND CLINICAL-DISEASE DURING TOPICAL R-837 TREATMENT OF GENITAL HSV-2 INFECTION [J].
HARRISON, CJ ;
JENSKI, L ;
VOYCHEHOVSKI, T ;
BERNSTEIN, DI .
ANTIVIRAL RESEARCH, 1988, 10 (4-5) :209-223
[10]  
Katz Stephen I., 1993, Journal of Dermatology (Tokyo), V20, P593